Jemperli performed better than Keytruda on some measures – such as tumours which express PD-L1 at levels between 1% and 49% and tumour proportion scores (TPS) above 50% – but Merck’s drug ...
The green light means that Keytruda is muscling in on territory held by GlaxoSmithKline's rival drug Jemperli (dostarlimab), which was approved for patients with recurrent or advanced endometrial ...
Keytruda has previously shown benefits in other ... Sloan Kettering in New York City found that immunotherapy drug Jemperli, ...